

1 **Biocide activity against urinary catheter pathogens (51 characters with**
2 **spaces-not to exceed 54 characters)**

3 **Biocides against urinary pathogens (31 characters)**

4 Sladjana **Malic**^{1#}, Rachael PC **Jordan**¹, Mark GJ **Waters**^{1,2}, David J **Stickler**³, David
5 **W Williams**¹,

6

7 ¹School of Dentistry, College of Biomedical and Life Sciences, Cardiff University,
8 Heath Park, Cardiff, CF14 4XY, UK.

9 ²MBI Wales, Bridgend, CF31 3YH, UK

10 ³School of Biosciences, Cardiff University, Cardiff, CF14 4XY, UK.

11

12 **Keywords:** *Proteus mirabilis*, biofilm formation, minimum inhibitory concentration,
13 tea tree oil, triclosan, eugenol

14

15 **Correspondence:**

16 #Dr Sladjana Malic, School of Healthcare Science, Manchester Metropolitan
17 University, Manchester M1 5GD, UK

18 S.malic@mmu.ac.uk

19

20

21

22

23

24 **Abstract**

25 Antimicrobial effects of essential oils against bacteria associated with urinary
26 catheter infection was assessed. Tests were performed on 14 different bacterial
27 species cultured either planktonically or as biofilms. Biofilms were found to be up to
28 8-fold more tolerant of the test agents. Higher antimicrobial tolerance was also
29 evident in tests conducted in artificial urine. Eugenol exhibited highest antimicrobial
30 effects against both planktonic cells and biofilms when compared with terpinen, tea
31 tree oil and cineole.

32

33 (73 words, cannot exceed 75 words)

34

35 Foley catheters are frequently used to drain urine from the bladder of patients with
36 urinary incontinence or neurological dysfunction. Whilst providing a valuable
37 function, urinary catheters also provide access for microorganisms to infect the
38 bladder and also undermine the basic host defences of the urinary tract. Importantly,
39 catheter-associated urinary tract infections (CAUTIs) represent the most frequently
40 encountered hospital acquired infection (1). *Proteus mirabilis* is a urease positive
41 bacterium that raises urine pH during infection. This allows struvite and apatite
42 crystal encrustation of the catheter which obstructs urine flow, potentially promoting
43 serious clinical complications. All currently available catheters are vulnerable to this
44 encrustation and there is no single effective preventative strategy (2-4).

45 Due to the increasing prevalence of antibiotic resistance, interest has arisen in the
46 therapeutic use of alternative medicines in combating infection (5-9). Naturally-
47 occurring biocides are effective in inactivating a wide variety of microorganisms as
48 they often target multiple bacterial sites and as such, are less prone to development
49 of resistance compared with antibiotics (10, 11). One possible approach to prevent
50 catheter encrustation would be to incorporate these biocides into catheter wash-out
51 solutions, into the catheter material itself or use the catheter retention balloon as a
52 reservoir for the delivery of the antimicrobial agent into the catheterised bladder (12-
53 16). Little is currently known about the susceptibility of *Proteus* to natural
54 antimicrobial agents hence the aim of this study was to examine antimicrobial activity
55 of several essential oils, namely tea tree oil, terpinen, cineole, and eugenol, against
56 *P. mirabilis* and other urease producing bacteria involved in CAUTIs. Activity of these
57 agents was tested against both planktonic cells and biofilms, as the latter frequently
58 exhibits enhanced resistance to traditional antimicrobials.

59 The isolates used in this study are presented in Table 1. The antimicrobial agents
60 tested were cineole, tea tree oil (TTO), terpinen, and eugenol. Overnight cultures of
61 test isolates were prepared in Mueller Hinton Broth (MHB) (17) or artificial urine
62 adjusted to pH 6.1, and containing 1% Tryptone Soya Broth (TSB)(18). Cultures
63 were adjusted to a 0.5 MacFarland standard (approximately 10^8 cells ml^{-1}) and
64 diluted 100-fold in MHB or artificial urine. Serial dilutions of the antimicrobial agents
65 were prepared in MHB or artificial urine supplemented with 0.002% (v/v) Tween 80
66 (Sigma Aldrich, UK). A 100- μl volume of each dilution of antimicrobial agent was
67 added to an equal volume of microbial suspension, giving antimicrobial
68 concentrations ranging from 0.008 to 8% (v/v). Controls included bacterial
69 suspensions containing no antimicrobial agent and uninoculated culture media. The
70 bacteria and antimicrobial agent were co-incubated aerobically in 96-well microtitre
71 plates for 24 h at 37°C. Microbial growth was determined by spectrophotometric
72 analysis (620_{nm}). Absorbance readings were standardised against 'microbial-free'
73 antimicrobial agent controls. The minimal inhibitory concentration (MIC) was defined
74 as the lowest concentration of antimicrobial agent which resulted in $\geq 80\%$ reduction
75 in absorbance compared to the antimicrobial-free controls (19).

76 A biofilm susceptibility test was also performed using the isolates described in Table
77 1. Isolates were incubated as described above, but without agitation to allow for
78 biofilm formation. Culture medium was removed and the biofilms were washed with
79 100- μ l phosphate buffered saline (PBS) to remove planktonic cells. Fresh culture
80 medium (100 μ l), containing antimicrobial agent at concentrations ranging from 0.008
81 to 8% (v/v), was added to each well. Controls, as previously described, were also
82 included. Biofilms were incubated in the presence of antimicrobial agent for 24 h
83 without agitation under the conditions described above before the supernatant was
84 removed and the biofilm washed ($\times 1$) with PBS. Fresh culture medium (100 μ l),
85 which did not contain antimicrobial agent, was added to the biofilms which were
86 disrupted by repeated pipetting. The turbidity (620_{nm}) of the re-suspended biofilm was
87 measured and again after incubation at 37°C for an additional 6 h and 24 h. The
88 relative growth of microorganisms was determined by the change in absorbance and
89 antibiofilm activity recorded as the lowest concentration of agent that demonstrated a
90 $\geq 80\%$ reduction in absorbance compared to the control. All experiments were
91 performed in triplicate on 3 separate occasions in MHB and artificial urine.

92

93 A summary of the results is presented in Table 1. Cineole and TTO had the lowest
94 antimicrobial activity against bacteria grown in MHB and were therefore not tested in
95 artificial urine. Highest antimicrobial activity by the essential oils against planktonic
96 growth in MHB occurred with eugenol and terpinen. However, when tested in artificial
97 urine, the activity of terpinen was noticeably reduced. There was also a higher
98 tolerance of biofilms (up to 8-fold) to most of the essential oils compared with their
99 planktonic equivalents. This increased biofilm resistance was least evident with

100 eugenol in MHB, but was apparent with eugenol (up to 32-fold) against biofilms in
101 artificial urine.

102

103 Urinary catheters provide a convenient means to drain urine from the bladder of
104 patients suffering from urinary incontinence or neurological dysfunction. However,
105 they are also associated with complications, as they provide access for bacteria from
106 a heavily contaminated external skin site to the bladder and kidneys (20). Catheters
107 also undermine the normal filling and emptying of the bladder which flushes out
108 microorganisms that might be contaminating the urethra. Furthermore, a reservoir of
109 residual urine remains in the bladder of catheterised patients, allowing continued
110 proliferation of contaminating organisms (21). CAUTIs are usually asymptomatic,
111 and because of the danger of promoting antibiotic resistance, catheter associated
112 bacteriuria is generally not treated with antibiotics (22-24). Elimination of *P. mirabilis*
113 by appropriate therapy as soon as it enters the catheterised urinary tract would
114 reduce the incidence of CAUTIs and improve the quality of life for many patients,
115 whilst also reducing the costs of managing the complications of catheter encrustation
116 and blockage (25). Several management and treatment strategies for CAUTIs have
117 been used, including limiting catheter use, removal of the catheter as soon as
118 possible, maintaining a closed drainage system, and use of alternative catheter
119 surfaces with anti-infective agents (23, 26). Unfortunately, no single effective strategy
120 for prevention of CAUTIs has yet been identified.

121 The purpose of this study was to assess the antimicrobial activity of several essential
122 oils against bacteria involved in CAUTIs. Based on these findings, further studies are
123 planned to incorporate these agents into urinary catheter materials to prevent
124 infection. The results of this study show that TTO, terpinen-4-ol, eugenol and

125 triclosan possessed antimicrobial activity against the majority of the organisms
126 tested in planktonic growth. A greatly reduced antimicrobial activity was, however,
127 noted when used to combat biofilms. The exception to this was eugenol, which
128 retained much of its activity against biofilms cultured in MHB. Recently, eugenol's
129 antibacterial activity against *P. mirabilis* was highlighted by Devi *et al.* (2013), who
130 demonstrated that eugenol altered the cell membrane integrity of *P. mirabilis* (27).
131 Our data also strengthens previous research regarding TTO activity, in particular
132 terpinen-4-ol, as the single active constituent of TTO, and its activity *in vivo* (9, 28,
133 29).

134 Whilst in our study, biofilms were more tolerant to these natural agents compared
135 with planktonic cells, sufficient antimicrobial effects were observed to warrant further
136 investigation into the clinical potential of these agents. These observations should
137 encourage clinical studies to examine the effect of washout solutions on the
138 blockage of long term catheterised patients. An alternative approach is the
139 incorporation of these agents into biomaterials used in catheter development,
140 thereby generating a catheter surface which could inhibit the growth and swarming of
141 *P. mirabilis*. There is the potential advantage to using such agents prophylactically
142 compared to antibiotics (*i.e* as they would not encourage the development of
143 antibiotic resistant organisms).

144 In conclusion, this study suggests that triclosan, terpinen-4-ol and eugenol inhibit
145 growth and swarming of *P. mirabilis* and may prove clinically useful for the treatment
146 of CAUTIs. However, more work is needed to validate the biocides for washout
147 solutions or their incorporation into urinary catheters.

148

149 **ACKNOWLEDGEMENTS:**

150 The authors acknowledge the financial support provided to this research by the
151 Welsh Assembly Government under the Academic Expertise for Business (A4B)
152 Collaborative Industrial Research Project (CIRP) scheme. The advice and support
153 provided to us by our industrial partners Great Bear Healthcare, Cardiff, UK, and MBI
154 Wales Ltd, Newport, UK, is also acknowledged.

155 **REFERENCES**

156 1. **Warren JW, S. L., H. J. J., and T. J. H.** 1989. The prevalence of urethral
157 catheterization in maryland nursing homes. Archives of Internal Medicine
158 **149**:1535-1537.

159 2. **Capewell, A. E., and S. L. Morris.** 1993. Audit of catheter management
160 provided by District Nurses and Continence Advisors. British Journal of
161 Urology **71**:259-264.

162 3. **Morris, N. S., D. J. Stickler, and C. Winters.** 1997. Which indwelling
163 urethral catheters resist encrustation by *Proteus mirabilis* biofilms? Br J
164 Urol **80**:58-63.

165 4. **Stickler, D., and R. C. Feneley.** 2013. The indwelling bladder catheter:
166 Attempts to prevent infection and the development of bacterial biofilms, p.
167 455-484. In T. Z. Moriarty, SAJ. and H. Busscher (ed.), Biomaterials
168 Associated Infection. Springer New York.

169 5. **Cowan, M. M.** 1999. Plant Products as Antimicrobial Agents. Clinical
170 Microbiology Reviews **12**:564-582.

171 6. **Hooper, S. J., M. A. O. Lewis, M. J. Wilson, and D. W. Williams.** 2011.
172 Antimicrobial activity of Citrox bioflavonoid preparations against oral
173 microorganisms. Br Dent J **210**:1-5.

174 7. **Moyle, J. R., J. M. Burke, A. Fanatico, J. A. Mosjidis, T. Spencer, K.**
175 **Arsi, I. Reyes-Herrera, A. Woo-Ming, D. J. Donoghue, and A. M.**
176 **Donoghue.** 2012. Palatability of tannin-rich sericea lespedeza fed to
177 broilers. The Journal of Applied Poultry Research **21**:891-896.

178 8. **Nikolic, M., T. Markovic, D. Markovic, T. Peric, J. Glamoclija, D.**
179 **Stojkovic, and M. Sokovic.** 2012. Screening of antimicrobial and
180 antioxidant activity of commercial *Melaleuca alternifolia* (tea tree)
181 essential oils. Journal of Medicinal Plants Research **6**:3852-3858.

182 9. **Papadopoulos, C. J., C. F. Carson, K. A. Hammer, and T. V. Riley.**
183 2006. Susceptibility of pseudomonads to *Melaleuca alternifolia* (tea tree)
184 oil and components. Journal of Antimicrobial Chemotherapy **58**:449-451.

185 10. **Sreenivasan, P., and A. Gaffar.** 2002. Antiplaque biocides and bacterial
186 resistance: a review. Journal of Clinical Periodontology **29**:965-974.

187 11. **Clatworthy, A. E., E. Pierson, and D. T. Hung.** 2007. Targeting
188 virulence: a new paradigm for antimicrobial therapy. Nat Chem Biol **3**:541-
189 548.

190 12. **Jones, G. L., C. T. Muller, M. O'Reilly, and D. J. Stickler.** 2006. Effect
191 of triclosan on the development of bacterial biofilms by urinary tract
192 pathogens on urinary catheters. J. Antimicrob. Chemother. **57**:266-272.

193 13. **Jones, G. L., A. D. Russell, Z. Caliskan, and D. J. Stickler.** 2005. A
194 Strategy for the Control of Catheter Blockage by Crystalline *Proteus*
195 *mirabilis* Biofilm Using the Antibacterial Agent Triclosan. European Urology
196 **48**:838-845.

197 14. **Stickler, D. J., and G. L. Jones.** 2008. Reduced Susceptibility of *Proteus*
198 *mirabilis* to Triclosan. Antimicrob. Agents Chemother. **52**:991-994.

199 15. **Stickler, D. J., G. L. Jones, and A. D. Russell.** 2003. Control of
200 encrustation and blockage of Foley catheters. Lancet **361**:1435-7.

201 16. **Bibby, J., A. Cox, and D. Hukins.** 1995. Feasibility of preventing
202 encrustation of urinary catheters. Cells Mater **2**:183-95.

203 17. **CLSI.** 2006. Clinical and Laboratory Standards Institute. M7-A7 Methods
204 for dilution antimicrobial susceptibility tests for bacteria that grow
205 aerobically. Clinical and Laboratory Standards Institute, Wayne, Pa.

206 18. **Griffith, D. P., D. M. Musher, and C. Itin.** 1976. Urease the primary
207 cause of infection-induced urinary stones. Investigative Urology **13**:346-
208 350.

- 209 19. **Espinel-Ingroff, A., and E. Canton.** 2007. Antifungal Susceptibility
210 Testing of Yeasts, p. 173-207. *In* R. Schwalbe, L. Steele-Moore, and A. C.
211 Goodwin (ed.). CRC Press 2007.
- 212 20. **Stickler, D.** 2005. Urinary catheters: Ideal sites for the development of
213 biofilm communities. *Microbiology today*:22-25.
- 214 21. **Feneley, R. C. L., C. M. Kunin, and D. J. Stickler.** 2012. An indwelling
215 urinary catheter for the 21st century. *BJU International* **109**:1746-1749.
- 216 22. **Stickler, D. J.** 2008. Bacterial biofilms in patients with indwelling urinary
217 catheters. *Nat Clin Pract Urol* **5**:598-608.
- 218 23. **Trautner, B. W., and R. O. Darouiche.** 2004. Role of biofilm in catheter-
219 associated urinary tract infection. *American Journal of Infection Control*
220 **32**:177-183.
- 221 24. **Tenke, P., B. Kovacs, T. E. Bjerklund Johansen, T. Matsumoto, P. A.**
222 **Tambyah, and K. G. Naber.** 2008. European and Asian guidelines on
223 management and prevention of catheter-associated urinary tract
224 infections. *International Journal of Antimicrobial Agents* **31, Supplement**
225 **1**:68-78.
- 226 25. **Stickler, D. J., and R. C. L. Feneley.** 2010. The encrustation and
227 blockage of long-term indwelling bladder catheters: a way forward in
228 prevention and control. *Spinal Cord* **48**:784-790.
- 229 26. **Choong, S., S. Wood, C. Fry, and H. Whitfield.** 2001. Catheter
230 associated urinary tract infection and encrustation. *International Journal of*
231 *Antimicrobial Agents* **17**:305-310.
- 232 27. **Devi, K. P., R. Sakthivel, S. A. Nisha, N. Suganthy, and S. K.**
233 **Pandian.** 2013. Eugenol alters the integrity of cell membrane and acts
234 against the nosocomial pathogen *Proteus mirabilis*. *Archives of Pharmacal*
235 *Research* **36**:282-292.
- 236 28. **Mondello, F., F. De Bernardis, A. Girolamo, A. Cassone, and G.**
237 **Salvatore.** 2006. In vivo activity of terpinen-4-ol, the main bioactive
238 component of *Melaleuca alternifolia* Cheel (tea tree) oil against azole-
239 susceptible and -resistant human pathogenic *Candida* species. *BMC*
240 *Infectious Diseases* **6**:158.
- 241 29. **Ramage, G., S. Milligan, D. F. Lappin, L. Sherry, P. Sweeney, C.**
242 **Williams, J. Bagg, and S. Culshaw.** 2012. Antifungal, cytotoxic, and
243 immunomodulatory properties of tea tree oil and its derivative
244 components: potential role in management of oral candidosis in cancer
245 patients. *Frontiers in microbiology* **3**:220.